RNS

Released : May 21, 2020 13:50   RNS Number : 6557N MaxCyte, Inc. 21 May 2020   THIS ANNOUNCEMENT IS RESTRICTED AND NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC
May 21, 2020
Released : May 14, 2020 07:00   RNS Number : 8406M MaxCyte, Inc. 14 May 2020       MaxCyte, Inc. ("MaxCyte" or the "Company")   MaxCyte to Present Poster Presentation on MCY-M11 at ASCO 2020 Annual Meeting     Gaithersburg, Maryland - 14 May 2020:   MaxCyte (LSE: MXCT), the global clinical-stage
May 14, 2020
Released : May 07, 2020 07:00   RNS Number : 1970M MaxCyte, Inc. 07 May 2020                                         FOR IMMEDIATE RELEASE   Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement   -  Agreement enables Caribou to utilize MaxCyte's ExPERT® platform for
May 07, 2020
Released : May 01, 2020 07:00   RNS Number : 5828L MaxCyte, Inc. 01 May 2020   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER
May 01, 2020
Released : April 30, 2020 17:39   RNS Number : 5668L MaxCyte, Inc. 30 April 2020   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER
Apr 30, 2020
Released : April 21, 2020 07:00   RNS Number : 2678K MaxCyte, Inc. 21 April 2020         MaxCyte, Inc. ("MaxCyte" or the "Company")   MaxCyte Reports Final Results for Year Ended 31 December 2019   Gaithersburg, Maryland - 21 April 2020:   MaxCyte (LSE: MXCT), the global clinical-stage cell-based
Apr 21, 2020
Released : April 09, 2020 07:00   RNS Number : 2917J MaxCyte, Inc. 09 April 2020       MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Provides Business Update Related to COVID-19 Pandemic -     Robust start to trading year with strong revenue results year-to-date 2020   -     Dosing of fourth
Apr 09, 2020
Released : March 24, 2020 07:00   RNS Number : 2942H MaxCyte, Inc. 24 March 2020                                         FOR IMMEDIATE RELEASE   MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement   ·     Agreement enables Allogene, a pioneer in the development of
Mar 24, 2020
Released : February 21, 2020 07:00   RNS Number : 6770D MaxCyte, Inc. 21 February 2020       NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Feb 21, 2020
Released : February 20, 2020 18:18   RNS Number : 6728D MaxCyte, Inc. 20 February 2020   SCHEDULE 6 AIM BLOCK ADMISSION RETURN / TOTAL VOTING RIGHTS   Please ensure the entries on this return are typed   a. Name of company   MaxCyte, Inc.   b. Name of scheme(s)   MaxCyte Long Term Incentive Plan  
Feb 20, 2020